B. Riley analyst Madison El-Saadi initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $179 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy Rating
- RBC lists biotech winners should RFK depart HHS
- RBC lists biotech winners should RFK departure HHS
- Axsome Therapeutics assumed with an Overweight at Wells Fargo
- Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO’s Market Expansion and Patent Strength